Topic Highlight
Copyright ©2007 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 7, 2007; 13(17): 2455-2460
Published online May 7, 2007. doi: 10.3748/wjg.v13.i17.2455
Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease
Jean-Claude Trinchet, Nathalie Ganne-Carrié, Pierre Nahon, Gisèle N'kontchou, Michel Beaugrand
Jean-Claude Trinchet, Nathalie Ganne-Carrié, Pierre Nahon, Gisèle N'kontchou, Michel Beaugrand, Service d'Hépato-Gastroentérologie, Hôpital Jean Verdier, Assistance Publique-Hôpitaux de Paris, UPRES EA 3409 and UPRES EA 3410, UFR SMBH, Université Paris 13, Bondy, France
Author contributions: All authors contributed equally to the work.
Correspondence to: Jean-Claude Trinchet, MD, PhD, Professor, Service d'Hépato-Gastroentérologie, Hôpital Jean Verdier-93143 Bondy Cedex, France.
Telephone: +33-1-48026280 Fax: +33-1-48026202
Received: March 7, 2007
Revised: March 8, 2007
Accepted: March 12, 2007
Published online: May 7, 2007

Hepatitis C virus (HCV) is a major cause of hepatocellular carcinoma (HCC) worldwide due to the high prevalence of HCV infection and the high rate of HCC occurrence in patients with HCV cirrhosis. A striking increase in HCC incidence has been observed during the past decades in most industrialized countries, partly related to the growing number of patients infected by HCV. HCC is currently the main cause of death in patients with HCV-related cirrhosis, a fact that justifies screening as far as curative treatments apply only in patients with small tumors. As a whole, treatment options are similar in patients with cirrhosis whatever the cause. Chemoprevention could be also helpful in the near future. It is strongly suggested that antiviral treatment of HCV infection could prevent HCC occurrence, even in cirrhotic patients, mainly when a sustained virological response is obtained.

Keywords: Hepatocellular carcinoma, Cirrhosis, Hepatitis C virus, Epidemiology, Screening, Treatment, Prevention